Infinium Global Research Blood Cancer Drugs Market | Page 5

1.3 Research Approaches
2. Executive Summary
3. Global Blood Cancer Drugs Market Overview
3.1 Introduction
3.2 Market Dynamics
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunities
3.3 Porter’s Five Forces Analysis
3.4 IGR – Growth Matrix Analysis
3.5 Competitive Landscape in the Blood Cancer Drugs Market
4. Global Blood Cancer Drugs Market Analysis, by Product 2017 – 2023
4.1 Rituaxan/Mabthera (Rituximab)
4.2 Gleevac/Glivec (Imatinib)
4.3 Revlimid (Lenalidomide)
4.4 Velcade (Bortezomib)
4.5 Tasigna (Nilotinib)
4.6 Pomalyst (Pomalidomide)
4.7 Vidaza (Azacitidine)
4.8 Kyprolis (Carfilzomib)
4.9 Adcetris (Brentuximab Vedotin)
Infinium Global Research